From nodule to differentiated thyroid carcinoma: Contributions of molecular analysis in 2012

Annales d'Endocrinologie

Volumn 73, Issue 3, 2012, Pages 155-164

  Albarel, Frédérique ^a   Conte Devolx, Bernard ^a   Oliver, Charles ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8;

ARTICLE; ASPIRATION BIOPSY; CANCER GROWTH; CANCER PROGNOSIS; CYTOLOGY; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; FALSE NEGATIVE RESULT; FOLLICULAR CARCINOMA; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR DIAGNOSIS; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; PAPILLARY CARCINOMA; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; TREATMENT FAILURE;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, CELL SURFACE; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863846153     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.03.002     Document Type: Article

References (87)

1. Vander J.B., Gaston E.A., Dawber T.R. The significance of non-toxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968, 69:537-540.
2. Ezzat S., Sarti D.A., Cain D.R., Braunstein G.D. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 1994, 154:1838-1840.
3. Wang C., Crapo L.M. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997, 26:189-218.
4. Wemeau J.L., Sadoul J.L., d'Herbomez M., Monpeyssen H., Tramalloni J., Leteurtre E., et al. Guidelines of the French society of endocrinology for the management of thyroid nodules. Ann Endocrinol (Paris) 2011, 72:251-281.
5. Leenhardt L., Grosclaude P. Epidemiology of thyroid carcinoma over the world. Ann Endocrinol (Paris) 2011, 72:136-148.
6. Horvath E., Majlis S., Rossi R., Franco C., Niedmann J.P., Castro A., et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009, 94:1748-1751.
7. Park J.Y., Lee H.J., Jang H.W., Kim H.K., Yi J.H., Lee W., et al. A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. Thyroid 2009, 19:1257-1264.
8. Oliver C., Vaillant-Lombard J., Albarel F., Berbis J., Veyrieres J.B., Sebag F., et al. What is the contribution of elastography to thyroid nodules evaluation?. Ann Endocrinol (Paris) 2011, 72:120-124.
9. Cibas E.S., Ali S.Z. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009, 19:1159-1165.
10. Baloch Z.W., LiVolsi V.A., Asa S.L., Rosai J., Merino M.J., Randolph G., et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008, 36:425-437.
11. Baloch Z.W., Fleisher S., LiVolsi V.A., Gupta P.K. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 2002, 26:41-44.
12. Mazzaferri E.L. Management of a solitary thyroid nodule. N Engl J Med 1993, 328:553-559.
13. Sassolas G., Hafdi-Nejjari Z., Schott A.M., Bournaud C., Peix J.L., Orgiazzi J., et al. Geographical correlation between incidence of benign disease and that of cancer of the thyroid among the population of the Rhone-Alpes Region of France. Eur J Endocrinol 2010, 162:127-135.
14. Yassa L., Cibas E.S., Benson C.B., Frates M.C., Doubilet P.M., Gawande A.A., et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007, 111:508-516.
15. Robertson M.L., Steward D.L., Gluckman J.L., Welge J. Continuous laryngeal nerve integrity monitoring during thyroidectomy: does it reduce risk of injury?. Otolaryngol Head Neck Surg 2004, 131:596-600.
16. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142.
17. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
18. Lewis C.M., Chang K.P., Pitman M., Faquin W.C., Randolph G.W. Thyroid fine-needle aspiration biopsy: variability in reporting. Thyroid 2009, 19:717-723.
19. Wang C.C., Friedman L., Kennedy G.C., Wang H., Kebebew E., Steward D.L., et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid 2011, 21:243-251.
20. Faggiano A., Caillou B., Lacroix L., Talbot M., Filetti S., Bidart J.M., et al. Functional characterization of human thyroid tissue with immunohistochemistry. Thyroid 2007, 17:203-211.
21. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
22. Mazzaferri E.L. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007, 13:498-512.
23. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21(Suppl. 2):S37-S43.
24. de Groot J.W., Links T.P., Plukker J.T., Lips C.J., Hofstra R.M. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006, 27:535-560.
25. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12:245-262.
26. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell 2004, 116:855-867.
27. Chiosea S., Nikiforova M., Zuo H., Ogilvie J., Gandhi M., Seethala R.R., et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009, 20:122-126.
28. Ciampi R., Knauf J.A., Kerler R., Gandhi M., Zhu Z., Nikiforova M.N., et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005, 115:94-101.
29. Adeniran A.J., Zhu Z., Gandhi M., Steward D.L., Fidler J.P., Giordano T.J., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30:216-222.
30. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404.
31. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
32. Karga H., Lee J.K., Vickery A.L., Thor A., Gaz R.D., Jameson J.L. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 1991, 73:832-836.
33. Motoi N., Sakamoto A., Yamochi T., Horiuchi H., Motoi T., Machinami R. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 2000, 196:1-7.
34. Schark C., Fulton N., Jacoby R.F., Westbrook C.A., Straus F.H., Kaplan E.L. N-ras 61 oncogene mutations in Hurthle cell tumors. Surgery 1990, 108:994-999. [discussion 9-1000].
35. Santoro M., Carlomagno F., Hay I.D., Herrmann M.A., Grieco M., Melillo R., et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992, 89:1517-1522.
36. Ciampi R., Giordano T.J., Wikenheiser-Brokamp K., Koenig R.J., Nikiforov Y.E. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer 2007, 14:445-452.
37. Jhiang S.M., Sagartz J.E., Tong Q., Parker-Thornburg J., Capen C.C., Cho J.Y., et al. Targeted expression of the RET/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996, 137:375-378.
38. Zhu Z., Ciampi R., Nikiforova M.N., Gandhi M., Nikiforov Y.E. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006, 91:3603-3610.
39. Nikiforov Y.E., Rowland J.M., Bove K.E., Monforte-Munoz H., Fagin J.A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997, 57:1690-1694.
40. Marotta V., Guerra A., Sapio M.R., Vitale M. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 2011, 165:499-507.
41. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000, 289:1357-1360.
42. Dwight T., Thoppe S.R., Foukakis T., Lui W.O., Wallin G., Hoog A., et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003, 88:4440-4445.
43. Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W., Tallini G., et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88:2318-2326.
44. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008, 93:1600-1608.
45. Nikiforova M.N., Chiosea S.I., Nikiforov Y.E. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 2009, 20:85-91.
46. Nikiforova M.N., Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009, 19:1351-1361.
47. Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., Haugen B.R., Klopper J.P., Zhu Z., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009, 94:2092-2098.
48. Zatelli M.C., Trasforini G., Leoni S., Frigato G., Buratto M., Tagliati F., et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009, 161:467-473.
49. Nam S.Y., Han B.K., Ko E.Y., Kang S.S., Hahn S.Y., Hwang J.Y., et al. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis. Thyroid 2010, 20:273-279.
50. Kim S.W., Lee J.I., Kim J.W., Ki C.S., Oh Y.L., Choi Y.L., et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010, 95:3693-3700.
51. Kim S.K., Hwang T.S., Yoo Y.B., Han H.S., Kim D.L., Song K.H., et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011, 96:658-664.
52. Salvatore G., Giannini R., Faviana P., Caleo A., Migliaccio I., Fagin J.A., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89:5175-5180.
53. Sciacchitano S., Paliotta D.S., Nardi F., Sacchi A., Andreoli M., Pontecorvi A. PCR amplification and analysis of ras oncogenes from thyroid cytologic smears. Diagn Mol Pathol 1994, 3:114-121.
54. Ohori N.P., Nikiforova M.N., Schoedel K.E., LeBeau S.O., Hodak S.P., Seethala R.R., et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol 2010, 118:17-23.
55. Ferraz C., Eszlinger M., Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab 2011, 96:2016-2026.
56. Nikiforov Y.E., Ohori N.P., Hodak S.P., Carty S.E., Lebeau S.O., Ferris R.L., et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011, 96:3390-3397.
57. Pallante P., Visone R., Ferracin M., Ferraro A., Berlingieri M.T., Troncone G., et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006, 13:497-508.
58. Griffith O.L., Melck A., Jones S.J., Wiseman S.M. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006, 24:5043-5051.
59. Durand S., Ferraro-Peyret C., Selmi-Ruby S., Paulin C., El Atifi M., Berger F., et al. Evaluation of gene expression profiles in thyroid nodule biopsy material to diagnose thyroid cancer. J Clin Endocrinol Metab 2008, 93:1195-1202.
60. Chudova D., Wilde J.I., Wang E.T., Wang H., Rabbee N., Egidio C.M., et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010, 95:5296-5304.
61. Puxeddu E., Moretti S., Elisei R., Romei C., Pascucci R., Martinelli M., et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004, 89:2414-2420.
62. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28:742-762.
63. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90:6373-6379.
64. Kim T.Y., Kim W.B., Gong G., Hong S.J., Shong Y.K. Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol (Oxf) 2005, 62:236-241.
65. Costa A.M., Herrero A., Fresno M.F., Heymann J., Alvarez J.A., Cameselle-Teijeiro J., et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008, 68:618-634.
66. Fugazzola L., Mannavola D., Cirello V., Vannucchi G., Muzza M., Vicentini L., et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004, 61:239-243.
67. Kim T.Y., Kim W.B., Rhee Y.S., Song J.Y., Kim J.M., Gong G., et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006, 65:364-368.
68. Elisei R., Ugolini C., Viola D., Lupi C., Biagini A., Giannini R., et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93:3943-3949.
69. Xing M., Clark D., Guan H., Ji M., Dackiw A., Carson K.A., et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009, 27:2977-2982.
70. Durante C., Puxeddu E., Ferretti E., Morisi R., Moretti S., Bruno R., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007, 92:2840-2843.
71. Riesco-Eizaguirre G., Gutierrez-Martinez P., Garcia-Cabezas M.A., Nistal M., Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006, 13:257-269.
72. Lee X., Gao M., Ji Y., Yu Y., Feng Y., Li Y., et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009, 16:240-245.
73. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090.
74. Garcia-Rostan G., Zhao H., Camp R.L., Pollan M., Herrero A., Pardo J., et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003, 21:3226-3235.
75. Hara H., Fulton N., Yashiro T., Ito K., DeGroot L.J., Kaplan E.L. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994, 116:1010-1016.
76. Volante M., Rapa I., Gandhi M., Bussolati G., Giachino D., Papotti M., et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 2009, 94:4735-4741.
77. Zhu Z., Gandhi M., Nikiforova M.N., Fischer A.H., Nikiforov Y.E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003, 120:71-77.
78. Tallini G., Santoro M., Helie M., Carlomagno F., Salvatore G., Chiappetta G., et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998, 4:287-294.
79. Santoro M., Papotti M., Chiappetta G., Garcia-Rostan G., Volante M., Johnson C., et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 2002, 87:370-379.
80. Durand S., Ferraro-Peyret C., Joufre M., Chave A., Borson-Chazot F., Selmi-Ruby S., et al. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinicopathological features. Endocr Relat Cancer 2009, 16:467-481.
81. French C.A., Alexander E.K., Cibas E.S., Nose V., Laguette J., Faquin W., et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003, 162:1053-1060.
82. Chou C.K., Chen R.F., Chou F.F., Chang H.W., Chen Y.J., Lee Y.F., et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010, 20:489-494.
83. Brilli L., Pacini F. Targeted therapy in refractory thyroid cancer: current achievements and limitations. Future Oncol 2011, 7:657-668.
84. Cabanillas M.E., Waguespack S.G., Bronstein Y., Williams M.D., Feng L., Hernandez M., et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010, 95:2588-2595.
85. Sherman S.I., Jarzab B., Cabanillas M.E., Licitra L.F., Pacini F., Martins R., et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Oncol 2011, 29.
86. Brose M.S., Troxel A.B., Redlinger M., Harlacker K., Redlinger C., Chalian A.A., et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol 2009, 27:301s. [abstr 6002].
87. Carpi A., Ferrari E., Toni M.G., Sagripanti A., Nicolini A., Di Coscio G. Needle aspiration techniques in preoperative selection of patients with thyroid nodules: a long-term study. J Clin Oncol 1996, 14:1704-1712.